Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Revenue (2018 - 2025)

Historic Revenue for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $17.2 million.

  • Exagen's Revenue rose 3787.48% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.6 million, marking a year-over-year increase of 1407.69%. This contributed to the annual value of $55.6 million for FY2024, which is 588.6% up from last year.
  • Latest data reveals that Exagen reported Revenue of $17.2 million as of Q3 2025, which was up 3787.48% from $17.2 million recorded in Q2 2025.
  • Exagen's Revenue's 5-year high stood at $17.2 million during Q3 2025, with a 5-year trough of $7.6 million in Q2 2022.
  • For the 5-year period, Exagen's Revenue averaged around $13.3 million, with its median value being $13.4 million (2023).
  • As far as peak fluctuations go, Exagen's Revenue tumbled by 4044.79% in 2022, and later soared by 8586.64% in 2023.
  • Over the past 5 years, Exagen's Revenue (Quarter) stood at $12.7 million in 2021, then rose by 1.17% to $12.8 million in 2022, then rose by 7.23% to $13.8 million in 2023, then fell by 0.8% to $13.7 million in 2024, then increased by 26.28% to $17.2 million in 2025.
  • Its Revenue stands at $17.2 million for Q3 2025, versus $17.2 million for Q2 2025 and $15.5 million for Q1 2025.